在成年患者中,慢性骨髓瘤新生体与体质NF1突变的临床病理特征和预后概况
Hamza Tariq1, Margarita Loxas1, Mir B Alikhan2
1Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
European journal of haematology
|March 28, 2025
概括
成年慢性髓瘤 (CMNs) 中的体内NF1突变与更高的绝对单细胞数量和复杂的遗传特征有关. 这些突变与明显较低的整体存活率有关,这表明NF1测试有助于风险评估.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 癌症遗传学 癌症遗传学
背景情况:
- 实体性神经纤维素瘤类型1 (NF1) 突变在儿科骨髓性瘤和成人急性骨髓性白血病 (AML) 中被研究.
- 关于NF1突变在成人慢性骨髓瘤 (CMNs) 中的临床病理和预后影响的数据有限,包括骨髓瘤综合征 (MDS),骨髓瘤扩散性瘤 (MPNs) 和骨髓瘤/骨髓瘤扩散性瘤 (MDS/MPNs).
研究的目的:
- 调查成年CMN体内NF1突变的临床病理特征和预后意义.
- 为了比较NF1突变CMN与NF1野生型 (NF1-WT) CMN.
主要方法:
- 2010年1月至2023年8月期间被诊断患有NF1突变CMN的成年患者的回顾性审查.
- 在NF1-突变和NF1-WT CMN组之间对临床病理学,遗传特征和整体存活率 (OS) 的比较.
主要成果:
- 确定了36个NF1突变的CMN (4.7%的所有CMN),包括19个MDS,4个MPN和13个MDS/MPN (所有CMML).
- 与NF1-WT对应物相比,NF1-突变的CMML和MDS表现出明显更高的绝对单细胞计数 (AMC),更频繁的复杂细胞类型,以及SRSF2和KRAS的突变增加.
- 与NF1-WTCMN (中位数4.8年) 相比,NF1-突变CMN的整体存活率明显较低 (中位数为2.05年).
结论:
- 具有NF1突变的成年CMN呈现高AMC,高风险分子细胞遗传特征和较差的生存结果.
- 对于被诊断为CMN的患者,NF1突变测试应被视为风险分层的一部分.
更多相关视频
相关概念视频
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...